Gerard P Norton

December 22, 2006 | New Jersey Law Journal

At stake in a case recently argued before the U.S. Supreme Court is whether a person of ordinary skill in the art at the time of an invention would have considered a new combination of elements obvious.

By Shahnam Sharareh, Gerard Bilotto, Jonathan R. Lagarenne and Gerard P. Norton

5 minute read

December 27, 2006 | National Law Journal

On Nov. 28, a showdown took place before the U.S. Supreme Court over the point at which an invention is obvious -- and therefore unpatentable. At stake in KSR International Co. v. Teleflex Inc. is the current standard: whether a person of ordinary skill in the art at the time of the invention would have considered the new combination of elements obvious. Attorneys Shahnam Sharareh, Gerard Bilotto, Jonathan R. Lagarenne and Gerard P. Norton of New Jersey's Fox Rothschild give their take on the case.

By Shahnam Sharareh, Gerard Bilotto, Jonathan R. Lagarenne and Gerard P. Norton

5 minute read

May 01, 2009 | Corporate Counsel

Now that the Democrats control the legislative agenda in Washington, D.C., the debate over a federal regulatory approval pathway for follow-on-biologics (similar to generic drugs) is again in play. A critical development in this area is the introduction of H.R. 1427, the "Promoting of Innovation and Access to Life Saving Medicine Act," a bipartisan bill recently introduced by U.S. representatives Henry Waxman (D-California), Frank Pallone (D-New Jersey), and Nathan Deal (R-Georgia).

By Gerard P. Norton, Shahnam Sharareh, and J. Mark Hand

7 minute read

April 08, 2009 | New Jersey Law Journal

Innovator biopharma companies must secure patent term provisions that would allow effective extension of their patents directed to the manufacturing process of their novel therapeutic biologics.

By Gerard P. Norton, J. Mark Hand and Shahnam Sharareh

7 minute read